JAMA dermatology最新文献

{"title":"BRAF Inhibition in Congenital Nevi and Neural Melanosis.","authors":"Brent J Doolan, Rebecca Levy, Tara McKeown, Anirban Das, Vijay Ramaswamy","doi":"10.1001/jamadermatol.2026.1629","DOIUrl":"10.1001/jamadermatol.2026.1629","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"859-861"},"PeriodicalIF":10.9,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148361000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathologic Features and Long-Term Outcomes of Adult Hypopigmented Mycosis Fungoides.","authors":"Jong Bin Park, Shamir Geller, Viviane Liao, Seda Purnak, Auris Huen, Swaminathan P Iyer, Olivia Pierog, Zachary Leibovit-Reiben, Aaron R Mangold, Jane Scribner, Sai M Talluru, Alyssa L Stockard, Jenna Vroman, Jeffrey Weiner, Pamela B Allen, Sima Rozati","doi":"10.1001/jamadermatol.2026.1793","DOIUrl":"10.1001/jamadermatol.2026.1793","url":null,"abstract":"<p><strong>Importance: </strong>Hypopigmented mycosis fungoides (HMF) is uncommon in adults, and data on clinicopathologic features and long-term outcomes remain sparse.</p><p><strong>Objective: </strong>To investigate the clinicopathologic features and outcomes of adults with HMF in a large multicenter cohort.</p><p><strong>Design, setting, and participants: </strong>This retrospective multicenter cohort study conducted from January 2011 to October 2023 at 6 US tertiary referral centers and included adults (18 years or older at diagnosis) with biopsy-confirmed HMF and hypopigmentation documented at diagnosis, with a median (range) follow-up of 39 (1-347) months. Data were analyzed from February to December 2025.</p><p><strong>Exposures: </strong>Clinical variant, immunophenotype predominance, and polymerase chain reaction-based T-cell receptor (TCR) gene rearrangement in peripheral blood and/or skin.</p><p><strong>Main outcomes and measures: </strong>Best overall response, defined as complete response, partial response, stable disease, or progressive disease, and progression to a higher stage.</p><p><strong>Results: </strong>The cohort included 224 adults with HMF (median [range] age, 44 [18-74] years), of whom 164 (73%) were women (60 men [27%]), 5 (2%) were Asian individuals, 1 (0.4%) was a Hispanic/Latino individual, 1 (0.4%) was a Middle Eastern individual, 19 (8%) were White individuals, and 186 (83%) were Black individuals; 219 (98%) presented with early-stage disease. Most had hypopigmented lesions only (159 [71%]), whereas 65 (29%) exhibited mixed-variant mycosis fungoides; outcomes were similar between groups. Among 141 patients with available immunophenotyping, 88 (63%) had CD8-positive predominance. Among 207 treated patients, most (179 [90%]) received skin-directed therapy alone. Among 198 evaluable patients, the best overall response was complete response for 52 (26%), partial response for 101 (51%), stable disease for 34 (17%), and progressive disease for 11 (6%). Over a median (range) follow-up of 39 (1-347) months, 14 of 224 patients (6%) experienced progression to a higher stage, including 5 of 219 patients (2%) with early-stage disease at baseline who experienced progression to advanced-stage disease. Peripheral blood TCR monoclonality was detected in 23 of 85 tested patients (27%) and was associated with poorer treatment response but not with disease progression.</p><p><strong>Conclusions and relevance: </strong>The finding of this cohort study suggest that adult HMF demonstrated a generally indolent course, with favorable response to skin-directed therapy, irrespective of immunophenotype or mixed-variant presentation. Peripheral blood TCR monoclonality was associated with lower treatment response but not disease progression.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"780-786"},"PeriodicalIF":10.9,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13276674/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148264362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic Proteomic Alterations and Predictive Biomarkers of Paroxetine Response in Refractory Rosacea: A Secondary Analysis of a Randomized Clinical Trial.","authors":"Ben Wang, Xinyi Deng, Yifan Zhang, Xin Xiao, Dan Jian, Wei Shi, Fangfen Liu, Zhixiang Zhao, Yan Tang, Mengting Chen, Zhili Deng, Ji Li, Yingxue Huang, Jundong Huang, Yiya Zhang","doi":"10.1001/jamadermatol.2026.1437","DOIUrl":"10.1001/jamadermatol.2026.1437","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Rosacea is a chronic inflammatory cutaneous disorder characterized by persistent erythema and vascular dysregulation. While paroxetine has shown clinical efficacy in reducing these symptoms, the systemic molecular mechanisms underlying its therapeutic response remain poorly characterized.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To investigate systemic proteomic alterations and identify potential predictive biomarkers in patients with refractory erythematous rosacea following paroxetine treatment.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This prospective plasma proteomic analysis was nested within a multicenter, randomized, double-blind, placebo-controlled clinical trial (Prospective Rosacea Refractory Erythema Randomized Clinical Trial [PRRERCT]). Participants included patients aged 18 to 65 years with refractory rosacea (Clinician's Erythema Assessment [CEA] score ≥3). Plasma samples were collected at baseline and after 12 weeks of treatment. The data for this study were analyzed between September 2025 and November 2025.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Interventions: &lt;/strong&gt;Participants received oral paroxetine, 25 mg per day, for a 12-week treatment period.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;Systemic protein expression profiles were analyzed using data-independent acquisition liquid chromatography-tandem mass spectrometry. Clinical response was evaluated using CEA and the Flushing Assessment Tool. Correlations between proteomic changes and clinical improvements were assessed, and predictive biomarkers were identified using receiver operating characteristic curve analysis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Among 24 participants (mean [SD] age, 35 [11] years; 24 [100%] female), paroxetine treatment significantly reduced mean (SD) CEA scores from 3.1 (0.3) to 2.3 (0.7) and Flushing Assessment Tool scores from 3.1 (0.6) to 2.0 (0.9) (P &lt; .001). Exploratory proteomic analysis revealed 497 candidate differentially expressed proteins after treatment. Downregulated proteins showed preliminary enrichment in pathways related to immune response activation, insulin receptor signaling, and neuronal remodeling. A subset of 98 reversed-response proteins was observed, primarily linked to synaptic vesicle cycles and vascular smooth muscle contraction. Proteomic alterations were associated with clinical improvement (65 proteins for erythema; 73 for flushing). Candidate biomarkers, notably OLFML3 (area under the receiver operating characteristic curve [AUC], 0.87 [95% CI, 0.70-1.00]) and IGFBP2 (AUC, 0.80 [95% CI 0.55-1.00]), demonstrated high predictive value for clinical response.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions and relevance: &lt;/strong&gt;In this secondary analysis of a randomized clinical trial, paroxetine treatment was associated with modulation of systemic neuro-vascular-immune networks in patients with rosacea. These exploratory findings provide preliminary mechanistic clues regarding the possible disease-modifying potential ","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"804-812"},"PeriodicalIF":10.9,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13276666/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148264416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Online vs In-Person Care for Atopic Dermatitis: A Randomized Clinical Trial.","authors":"April W Armstrong, Alyssa M Roberts, Gina Kostandy, Farzana Choudhury, Danielle Yee, Minnelly Luu, Madison E Jones, Elmar R Alizadeh, Jonathan Cotliar, Mary-Margaret Chren, Joel M Gelfand, Myles Cockburn, Jason N Doctor","doi":"10.1001/jamadermatol.2026.1959","DOIUrl":"10.1001/jamadermatol.2026.1959","url":null,"abstract":"<p><strong>Importance: </strong>Accessible and effective management of atopic dermatitis (AD) across geographic boundaries is important. Scalable, collaborative care models that integrate patients, primary care practitioners, and specialists remain an unmet need.</p><p><strong>Objective: </strong>To determine whether an online, team-based connected health (TCH) model provides equivalent improvements in AD severity compared to in-person care.</p><p><strong>Design, setting, and participants: </strong>In this pragmatic, randomized clinical equivalence trial, 300 patients with AD were enrolled from 8 outpatient dermatology clinics in California from August 2019 to May 2024 and randomized 1:1 to online or in-person care. Eligible participants were at least 1 year old and had a physician diagnosis of AD, internet and photograph access, and established or new clinician care.</p><p><strong>Intervention: </strong>The TCH model provided asynchronous, online access to dermatologists. Dermatologists reviewed patients' clinical histories and photographs and provided assessments and treatment recommendations online. The control arm provided conventional, in-person care.</p><p><strong>Main outcomes and measures: </strong>The primary outcome was 12-month change in the EASI (Eczema Area and Severity Index); secondary outcomes were changes in the POEM (Patient-Oriented Eczema Measure) and validated vIGA (Investigator Global Assessment), assessed quarterly.</p><p><strong>Results: </strong>Among 300 adults and children with AD (mean [SD] age, 34.6 [17.7] years; 211 [70.3%] female), 149 were assigned to TCH and 151 to in-person care. The difference in mean change between the 2 groups was -0.01 (95% CI, -0.22 to 0.20) for the EASI, 0.38 (95% CI, 0.03-0.73) for the POEM, and 0.06 (95% CI, 0.00-0.11) for the vIGA. All differences fell within prespecified equivalence margins.</p><p><strong>Conclusions and relevance: </strong>In this randomized clinical trial, the online TCH model resulted in equivalent improvements in AD signs and symptoms compared to in-person care. Telehealth models may serve as effective tools for managing chronic diseases like AD.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT03981926.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"795-803"},"PeriodicalIF":10.9,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13294821/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148308072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GLP-1 Receptor Agonists in Hidradenitis Suppurativa-Emerging Opportunities for Comorbidity Management?","authors":"Haley B Naik, Diana Thiara","doi":"10.1001/jamadermatol.2026.1882","DOIUrl":"10.1001/jamadermatol.2026.1882","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"773-774"},"PeriodicalIF":10.9,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148360927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a Core Outcome Domain Set for Facial Aging.","authors":"McKenzie A Dirr, Areeba Ahmed, Daniel I Schlessinger, Vanessa Lazaro-Camp, Sabrina Smith, Thanvi Gullapalli, Doroteja Dragovic, Joycie Chang, Elizabeth Zhang, Murad Alam, Noor Anvery, Rachel E Christensen, Sarah A Ibrahim, Bianca Y Kang, Clarissa Wong, Sanjana Iyengar, Arianna F Yanes, Jill Cotseones, Hovik J Ashchyan, Payal M Patel, Umar A Sheikh, Matthew J Franklin, Courtney C Hanna, Sarah G Chiren, Jochen Schmitt, Karina C Furlan, Macrene Alexiades, Raed Alhusayen, Tina S Alster, Kenneth Beer, Vince Bertucci, Jason D Bloom, César A Briceño, Vivian Bucay, Kimberly J Butterwick, Cartier Hugues, Gabriela Casabona, Karen L Connolly, Sebastian Cotofana, Martha Laurin Council, Sue Ellen Cox, Monica Darmanescu, Koenraad De Boulle, Shraddha Desai, Lisa M Donofrio, Jeffrey S Dover, Zoe Draelos, Daniel B Eisen, Moetaz El-Domyati, Yehia El-Garem, John Fischer, Rebecca Fitzgerald, Daniel P Friedmann, Hassan Galadari, Hayes B Gladstone, Mitchel P Goldman, Greg J Goodman, Jeremy B Green, Shlomit Halachmi, C William Hanke, Shannon Humphrey, Sherrif F Ibrahim, Jared Jagdeo, Shang I Brian Jiang, Julie K Karen, Arielle Kauvar, Abdul-Ghani Kibbi, John V S Kim, Jenny Kim, Davi de Lacerda, Gary Lask, Grace M Lopez, Mary P Lupo, Kavita Mariwalla, Seth Matarasso, Lally Mekokishvili, Rhoda S Narins, Patricia Ogilvie, Jeffrey S Orringer, Tammy H Osaki, David Ozog, Theresa Pacheco, Kristel Polder, Anthony M Rossi, Neil Sadick, Nazanin Saedi, Joel Schlessinger, Jaishree Sharad, Manjunath M Shenoy, Rodney Sinclair, Nowell Solish, Miriam Emily Piansay-Soriano, Omotara Sulyman, Rolf-Markus Szeimies, Elizabeth L Tanzi, Amy Forman Taub, Mark B Taylor, J Regan Thomas, Luis Torezan, Antonella Tosti, Dany Touma, Ada Regina Trindade de Almeida, Maya Vedamurthy, Giovanni Viana, Abigail Waldman, Susan H Weinkle, Robert Weiss, Emily Poon, Ian A Maher, Todd V Cartee, Joseph F Sobanko, Jamie J Kirkham","doi":"10.1001/jamadermatol.2026.1697","DOIUrl":"10.1001/jamadermatol.2026.1697","url":null,"abstract":"<p><strong>Importance: </strong>Currently, there are no standardized outcome domains or measures in clinical trials for facial aging. Heterogeneity in outcome domains and measurement instruments across clinical trials creates difficulty in directly comparing interventions, determining superior therapies, and developing high-quality meta-analyses.</p><p><strong>Objective: </strong>To develop a core outcome set (COS) of essential domains to be reported in clinical trials evaluating the efficacy of interventions for facial aging.</p><p><strong>Evidence review: </strong>PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials, and CINAHL were searched from September 2005 to September 2015. An updated search of the same databases was performed from September 2015 to February 2026. Studies were included if (1) they were randomized clinical trial or controlled clinical trial in design, (2) they assessed the efficacy or safety of an intervention for facial aging, (3) they were published in English, and (4) they involved human participants. Complementary sources, including patient interviews, were used to capture further relevant outcomes. Two rounds of Delphi surveys, followed by consensus meetings, were used to identify outcome domains considered most important by both patient and physician stakeholders.</p><p><strong>Findings: </strong>The final COS consists of 6 outcome domains: (1) overall convenience of treatment; (2) time to return to normal work and social activity; (3) overall assessment of focused area of treatment (at the point in time when treatment is expected to provide peak benefit); (4) duration of treatment effect; (5) severity of persistent local or systemic adverse events, including pigmentary change, skin texture change, delayed healing, scarring, and serious adverse events; and (6) patient satisfaction with treatment.</p><p><strong>Conclusions and relevance: </strong>The 6 outcome domains identified through a Delphi consensus are recommended for reporting in future facial aging trials to ensure that outcomes that matter most to patients and clinicians are measured and that results are comparable across interventions.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"829-836"},"PeriodicalIF":10.9,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148264333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant Capecitabine in Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck.","authors":"Savanah Haidar, Alex Mlynarek, Philippe Lefrancois, Osama Roshdy, Manish Khanna, Geneviève Fortier-Riberdy, Keith Richardson, Livia Florianova, Marc Pusztaszeri, Derin Caglar, Nader Sadeghi, Michael Hier, Khalil Sultanem, Christina Tsien, Nathaniel Bouganim, Khashayar Esfahani, Marco A Mascarella","doi":"10.1001/jamadermatol.2026.1331","DOIUrl":"10.1001/jamadermatol.2026.1331","url":null,"abstract":"<p><strong>Importance: </strong>The incidence of cutaneous squamous cell carcinoma of the head and neck (cSCCHN) has increased, including among those with high-risk disease. Delays to access and initiation of care are associated with disease progression and worse outcomes. Capecitabine has previously been shown to be effective antitumor activity with low toxic effects.</p><p><strong>Objective: </strong>To evaluate the efficacy and tolerability of neoadjuvant capecitabine (NC) in advanced cSCCHN by evaluating the clinical and pathologic stage migration.</p><p><strong>Design, setting, and participants: </strong>This prospective case series was conducted from January 2024 to September 2025 at 2 academic centers in Montreal, Canada, and included consecutive patients with advanced cSCCHN who were awaiting surgery. The data were analyzed in November 2025.</p><p><strong>Intervention: </strong>Two cycles of NC (1000 mg, twice daily, on days 1-14, followed by a 1-week rest period) were administered according to the Capecitabine Prior to Tumor Resection in ENT Oncology (CAPTURE) protocol, with surgical resection performed within 1 to 2 weeks after treatment completion.</p><p><strong>Main outcomes and measures: </strong>Clinical tumor response and clinical to pathologic stage migration, defined as the comparison of initial clinical stage with the postsurgical pathologic stage.</p><p><strong>Results: </strong>The mean (SD) age of the cohort of 15 patients was 77 (8.1) years; 6 patients (40%) were female, and 9 patients (60%) were male. Clinical tumor regression was observed in 10 of 15 patients (67%). Among those who underwent resection, 5 (42%) achieved a complete pathologic response. Two patients avoided surgery due to complete treatment response and opted to receive radiotherapy. Nonresponse occurred for 5 patients, including 1 patient who experienced progression to metastatic disease. No grade 3 or higher capecitabine-related toxic effects were reported.</p><p><strong>Conclusions: </strong>This case series found that NC demonstrated significant tumor regression and pathologic response without severe treatment-related toxic effects. NC may be an effective treatment option for providing disease control and tumor downstaging in patients with advanced cSCCHN.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"813-817"},"PeriodicalIF":10.9,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13217255/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148030623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intraocular Pressure During Short-Term Topical or Systemic Corticosteroid Treatment: Analysis of 3 Randomized Clinical Trials.","authors":"Diva Amiri, Pernille H Hellmann, Jacob P Thyssen, Lone Skov, Miriam Kolko, Lise Gether","doi":"10.1001/jamadermatol.2026.1183","DOIUrl":"10.1001/jamadermatol.2026.1183","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Increased intraocular pressure (IOP) is a known adverse effect of corticosteroid use and may lead to corticosteroid-induced glaucoma. However, clinical evidence on the impact of topical corticosteroids (TCS) on IOP is limited.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To evaluate changes in IOP during short-term treatment with periocular and whole-body TCS (studies 1 and 2) and systemic corticosteroids (study 3).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This report includes the findings of 3 randomized clinical trials (RCTs) conducted at Herlev-Gentofte Hospital, University of Copenhagen (Denmark). Study 1 was an open-label RCT of patients with periocular atopic dermatitis (AD) and healthy controls, conducted from October 2021 to August 2023. Study 2 was a double-blind active comparator RCT of patients with AD conducted from September 2019 to March 2021. Study 3 was a double-blind RCT of male individuals with overweight or obesity and without diabetes conducted from December 2019 to June 2021. Data were analyzed from October 2024 to April 2025.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Interventions: &lt;/strong&gt;In study 1, patients with AD and healthy controls applied periocular hydrocortisone (1.0%) cream or hydrocortisone-17-butyrate (0.1%) cream for 4 weeks; another group of healthy controls received no treatment. In study 2, patients with AD completed 2 weeks of whole-body betamethasone 17-valerate (0.1%) plus placebo or tacrolimus (0.1%) twice daily, followed by 4 weeks of twice-weekly treatment. In study 3, patients with AD received 10 days of oral placebo or prednisolone (50 mg) or prednisolone (50 mg) plus curcumin (400 mg).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcome: &lt;/strong&gt;Change in IOP-the primary end point in study 1 and a predefined secondary end point in studies 2 and 3.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Study 1 included 24 patients, 8 with periocular atopic dermatitis (AD) and 16 healthy controls; study 2 included 36 patients with AD; and study 3 included 24 male individuals with overweight or obesity and without diabetes. The analysis of the 3 studies included a total of 84 participants (34 female [40.5%] and 50 male [59.5%] patients) with comparable baseline characteristics (mean [SD] age, 32 [9], 28 [10], and 46 [14] years). In study 1, right eye IOP significantly decreased in patients with AD after treatment compared to untreated controls (-2.5 mm Hg; 95% CI, -3.9 to -1.1 mm Hg; P = .002). No significant changes were observed in the left eye or among treated healthy controls. In studies 2 and 3, IOP remained stable, with no significant changes.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions and relevance: &lt;/strong&gt;In these 3 RCTs, short-term corticosteroid use, whether topical or systemic, did not appear to increase IOP. These findings support the ocular safety of short-term corticosteroid use.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Trial registrations: &lt;/strong&gt;EU Clinical Trials Register Identifier: 2020-000252-35; ClinicalTrials.gov Identifier: NCT04114097 and NCT04315350.&lt;/","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"818-823"},"PeriodicalIF":10.9,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13173421/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147929744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emergomycosis Without Immunodeficiency.","authors":"Zhongyu Chen, Yun Guo, Qiutian Lei, Limei Yuan, Binbin Yang, Danqi Deng","doi":"10.1001/jamadermatol.2026.1513","DOIUrl":"10.1001/jamadermatol.2026.1513","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"856-859"},"PeriodicalIF":10.9,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148264327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Topical Preparations for Moderate to Severe Rosacea Treatment: A Systematic Review and Network Meta-Analysis.","authors":"Anissa Valentina Amstutz, Abizairie Sánchez-Feliciano, Eliza Dewey, Ursula Biba, Lana Salloum, John S Barbieri","doi":"10.1001/jamadermatol.2026.2062","DOIUrl":"10.1001/jamadermatol.2026.2062","url":null,"abstract":"<p><strong>Importance: </strong>Comparative efficacy and tolerability of topical therapies for rosacea remain incompletely characterized, particularly for novel agents such as encapsulated benzoyl peroxide.</p><p><strong>Objective: </strong>To compare the efficacy and tolerability of topical treatments for moderate to severe rosacea through a systematic review and network meta-analysis of randomized clinical trials (RCTs).</p><p><strong>Data sources: </strong>CENTRAL (Cochrane Central Register of Controlled Trials), MEDLINE via Ovid, Web of Science, and Embase databases were searched from inception through August 6, 2025, and supplemented by manual screening of references.</p><p><strong>Study selection: </strong>RCTs published in English that included adults with moderate to severe rosacea and assessed topical therapies for rosacea were included.</p><p><strong>Data extraction and synthesis: </strong>Two reviewers independently extracted data and assessed risk of bias using the Cochrane Risk of Bias tool, version 2.0. Data were synthesized using random-effects network meta-analyses. Treatment rankings were estimated using SUCRA (surface under the cumulative ranking) values. Certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation framework.</p><p><strong>Main outcomes and measures: </strong>Prespecified primary outcomes were mean change in absolute lesion count, Investigator Global Assessment (IGA) success, and discontinuation due to adverse events or effects. Secondary outcomes included patient-reported measures and clinician-assessed erythema.</p><p><strong>Results: </strong>Of 2858 records screened, 32 RCTs met inclusion criteria, comprising a total of 11 399 adults treated with 10 topical interventions. Most studies had a 8- to 16-week follow-up period. Compared with metronidazole, ivermectin and encapsulated benzoyl peroxide demonstrated greater reductions in lesion count (mean difference [MD], 4.17; 95% CI, 1.85-6.48; and MD, 4.14; 95% CI, 0.62-7.66, respectively) and higher likelihood of IGA success (MD, 10.31; 95% CI, 2.85 to 17.77; and MD, 15.51; 95% CI, 2.35-28.68, respectively). Frequency of discontinuation due to adverse events were similar between treatments, although discontinuation was more frequent with encapsulated benzoyl peroxide than metronidazole (MD, 8.33; 95% CI, 0.45-16.22). Limited data precluded robust quantitative synthesis of patient-reported outcomes and erythema outcomes.</p><p><strong>Conclusions and relevance: </strong>In this systematic review and network meta-analysis, topical ivermectin and encapsulated benzoyl peroxide were more efficacious than metronidazole for rosacea, although encapsulated benzoyl peroxide was also associated with higher discontinuation due to adverse events. Future trials should evaluate long-term efficacy, tolerability, and standardized patient-reported outcomes.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"787-794"},"PeriodicalIF":10.9,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13324944/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148360984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}